
A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
In this video, Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
For more information about Dr. Fein's controversial op-ed on 340B pricing, see